The Quantellect read.As of Nov 18, 2026, 3 active firms cover CalciMedica, Inc. Common Stock: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $9.00 to $10.00, so the covering firms are broadly aligned. The average target of $9.50 sits 685% above the current $1.21. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.41 next quarter toward $-2.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 18, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.50
+685.1% upside
Average target across 2 active firms as of Nov 18, 2026 vs $1.21 current
Highest Target$10.00
Average Target$9.50
Lowest Target$9.00
Detailed analyst forecasts for CALC
Showing 1–2 of 2 named analysts shown · 3 active firms in the rating projection
As of Nov 18, 2026, 2 of 3 active firms rate CALC a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CALC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.41 – $-0.41 · 1 analysts · -88% YoY
Next period, 1 analysts expect CalciMedica, Inc. Common Stock to earn $-0.41 a share (range $-0.41 – $-0.41), versus $-3.45 a year earlier. Full-year consensus is $-1.91, growing to $-2.19 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering CalciMedica, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CALC.
#1
Vamil Divan
Guggenheim · Rank #211
Buy
$9.00+643.8% to target
Overall win rate
48%
+ Follow
#2
Leland Gershell
Oppenheimer · Rank #404
Buy
$10.00+726.4% to target
Overall win rate
35%
+ Follow
CALC stock forecast FAQ
What is CALC's average 12-month price target?+
The 2 active firms with a live target average $9.50 for CalciMedica, Inc. Common Stock over the next 12 months, ranging from a $10.00 high to a $9.00 low, as of Nov 18, 2026.
Is CALC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 18, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CALC?+
The Street-high target is $10.00 (Oppenheimer), and the Street-low is $9.00 (Guggenheim). The average of all 2 active-firm targets is $9.50.
How many active Wall Street firms cover CALC?+
3 active firms have a recognized rating on CalciMedica, Inc. Common Stock as of Nov 18, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CALC?+
Among analysts who currently cover CALC, Vamil Divan of Guggenheim has the strongest overall Quantellect track record (Rank #211). Their current call is Buy with a $9.00 target.
What is CalciMedica, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.41 – $-0.41) across 1 analysts. Full-year EPS is projected at $-1.91, rising to $-2.19 the following year.
How much revenue is CalciMedica, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CALC lately?+
As of Nov 18, 2026, 2 of 3 active firms rate CALC a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CALC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.